drugset / Trial / NCT01323101

Doxycycline Effects on Inflammation in Cystic Fibrosis

NCT01323101

Phase 4 Completed 21 enrolled University of Southern California
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Doxycycline is known to exhibit immune modulatory activities beyond its antibacterial effects. In particular, doxycycline is a potent inhibitor of matrix metalloproteinase 9, which is a protease derived largely from neutrophils. Recent studies demonstrate a significant correlation between pulmonary disease severity and sputum concentrations of MMP-9 in patients with CF. In addition, sputum MMP-9 levels are associated with airway remodeling in CF. The goal of this study is to determine the therapeutic potential of doxycycline in modulating host airway inflammation in patients with CF. Specifically, the study will characterize the PK /PD of doxycycline, evaluate the safety of short term therapy, and explore the concentration effect relationship between doxycycline exposure and sputum biomarker levels.

Timeline

Start
2008-04
Primary completion
2010-12
Completion
2010-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Doxycycline Small molecule 40 mg Intravenous
Subject Doxycycline Small molecule 100 mg Intravenous
Subject Doxycycline Small molecule 200 mg Intravenous

Indications